Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Roche Group

- PMLiVE

Genentech’s US manufacturing facility advances with construction milestone

The facility is part of Roche and Genentech’s broader $50bn commitment to US R&D and manufacturing infrastructure

- PMLiVE

Genentech increases investment to $2bn for US manufacturing site

Roche and Genentech have a current commitment of $50bn for US manufacturing

- PMLiVE

Genentech reports positive trial results for obesity treatment

The treatment is designed to tackle obesity by reducing appetite and regulating blood sugar

- PMLiVE

Amgen agrees to lower prescription drug costs in deal with US government

The company has invested $40bn in US R&D and manufacturing in the past seven years

- PMLiVE

Lilly announces plans for $6bn US manufacture facility

The site is the third of four new US sites that Lilly has announced

- PMLiVE

AstraZeneca announces $2bn investment in US manufacturing

The new and expanded facilities will support production of rare disease drug treatments

- PMLiVE

Genentech announces positive clinical results for BTK inhibitor MS treatment

Multiple sclerosis affects more than 2.9 million people globally

- PMLiVE

AstraZeneca to invest $4.5bn in US manufacturing facility

The investment will further support the company’s growing oncology pipeline

- PMLiVE

Genentech starts construction on manufacturing facility in North Carolina, US

The $700m project is part of Roche’s $50bn investment in the US

- PMLiVE

Roche’s Genentech enters $765m autoimmune disease partnership with Repertoire

The collaboration will leverage Repertoire’s immune mapping DECODE platform

- PMLiVE

Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke

TNKase is the first stroke medicine to be approved by the regulator in almost three decades

- PMLiVE

Roche’s Genentech acquires Regor Pharmaceuticals’ CDK inhibitors for $850m upfront

One of the candidates included in the deal has already shown promise in a phase 1a advanced breast cancer study

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links